{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Number of unique patients who had a treatment related (possible, probable or definite) adverse event with grade \\>= 3 using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.","groups":[{"description":"Brentuximab Vedotin 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Negative/Unknown cohort.","id":"OG000","title":"CD30 Negative/Unknown"},{"description":"Brentuximab Vedotin 1.8 mg/ kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Positive cohort.","id":"OG001","title":"CD30 Positive"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Number of Patients With Treatment Related Adverse Events Grade 3 or Above","type":"SECONDARY","unitOfMeasure":"Participants"}